Osteoporosis in postmenopausal women
Conditions
Interventions
Trial group: received DTx+ disuzumab injection (Lukexin) 60mg each time
Control group:Disuzumab injection (Lukexin) 60mg each time
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
Female
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Voluntarily sign an informed consent form (ICF) and be able to comply with treatment protocols, visits, laboratory tests, and other requirements specified in the study; (2) Age =45 years, =75 years; (3) Postmenopausal women; (4) Bone mineral density test value T value: -2.5 ~ -4.0.
Exclusion criteria
Exclusion criteria: (1) Allergic reaction to any component of disuzumab injection; (2) Patients with hypocalcemia; (3) Patients whose spinal x-rays reveal any severe or more than two moderate vertebral fractures; (4) Hearing or visual impairment, physical disability and Parkinson's disease; (5) expression disorder or mental illness; (6) It is estimated that the compliance of participants to participate in the clinical study is insufficient; (7) Participants who are currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density;roentgenogram; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pittsburgh sleep index;Heart sunshine index;Quality of Life Scale (SF-12);Standing and Walking Test Assessment Scale (TUG);Muscle strength test;FRAX Risk Assessment; | — |
Countries
China
Contacts
Public ContactFuxing Pei
West China Hospital of Sichuan University
Outcome results
None listed